AIM: Blockade of the renin-angiotensin-aldosterone system (RAAS) affects both the glomerulus and tubules. We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP). METHODS: A substudy of a double-masked, randomized, cross-over study including 52 patients with type 2 diabetes, hypertension and microalbuminuria. After 2 months washout of all antihypertensive medication except bendroflumethiazid, patients were treated in random order with irbesartan 300, 600 and 900 mg for 2 months. END POINTS: Urinary tubular markers at baseline and after each treatment period (ELISA), 24-h blood pressure, glomerular filtration rate (GFR, (51)CrEDTA) and 24-h urine albumin excretion (UAER). RESULTS:Fifty-two patients completed the study (41 male). Age (mean (SD)): 58(10) years and diabetes duration 13(8) years. Baseline GFR was 101(24) and UAER (geometric mean [95%CI]) 133 (103-172) mg/24 h. With increasing doses of irbesartan (300, 600, 900 mg) u-KIM1 was reduced with 15%, 10% and 15% (p = 0.07 between 300 mg vs. baseline and no difference between doses). Patients with high u-KIM1 at baseline (above median) had a 32% reduction in u-KIM1 during treatment (p = 0.01). No significant decline in U-NGAL compared to baseline. U-LFABP increased during treatment (p < 0.01). CONCLUSIONS: Irbesartan treatment reduced levels of the tubular marker u-KIM1 in patients with type 2 diabetes and microalbuminuria. u-NGAL changed insignificantly and u-LFABP increased. More studies with longer follow up are needed to determine the role of tubular markers in monitoring treatment effect and prediction of prognosis in diabetic nephropathy.
RCT Entities:
AIM: Blockade of the renin-angiotensin-aldosterone system (RAAS) affects both the glomerulus and tubules. We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP). METHODS: A substudy of a double-masked, randomized, cross-over study including 52 patients with type 2 diabetes, hypertension and microalbuminuria. After 2 months washout of all antihypertensive medication except bendroflumethiazid, patients were treated in random order with irbesartan 300, 600 and 900 mg for 2 months. END POINTS: Urinary tubular markers at baseline and after each treatment period (ELISA), 24-h blood pressure, glomerular filtration rate (GFR, (51)CrEDTA) and 24-h urine albumin excretion (UAER). RESULTS: Fifty-two patients completed the study (41 male). Age (mean (SD)): 58(10) years and diabetes duration 13(8) years. Baseline GFR was 101(24) and UAER (geometric mean [95%CI]) 133 (103-172) mg/24 h. With increasing doses of irbesartan (300, 600, 900 mg) u-KIM1 was reduced with 15%, 10% and 15% (p = 0.07 between 300 mg vs. baseline and no difference between doses). Patients with high u-KIM1 at baseline (above median) had a 32% reduction in u-KIM1 during treatment (p = 0.01). No significant decline in U-NGAL compared to baseline. U-LFABP increased during treatment (p < 0.01). CONCLUSIONS:Irbesartan treatment reduced levels of the tubular marker u-KIM1 in patients with type 2 diabetes and microalbuminuria. u-NGAL changed insignificantly and u-LFABP increased. More studies with longer follow up are needed to determine the role of tubular markers in monitoring treatment effect and prediction of prognosis in diabetic nephropathy.
Authors: Gudeta D Fufaa; E Jennifer Weil; Robert G Nelson; Robert L Hanson; Joseph V Bonventre; Venkata Sabbisetti; Sushrut S Waikar; Theodore E Mifflin; Xiaoming Zhang; Dawei Xie; Chi-Yuan Hsu; Harold I Feldman; Josef Coresh; Ramachandran S Vasan; Paul L Kimmel; Kathleen D Liu Journal: Diabetologia Date: 2014-10-15 Impact factor: 10.122
Authors: Girish N Nadkarni; Veena Rao; Faramarz Ismail-Beigi; Vivian A Fonseca; Sudhir V Shah; Michael S Simonson; Lloyd Cantley; Prasad Devarajan; Chirag R Parikh; Steven G Coca Journal: Clin J Am Soc Nephrol Date: 2016-05-17 Impact factor: 8.237
Authors: Tomás P Griffin; William Patrick Martin; Nahidul Islam; Timothy O'Brien; Matthew D Griffin Journal: Curr Diab Rep Date: 2016-05 Impact factor: 4.810
Authors: Aleksandra Tonkonogi; Axel C Carlsson; Johanna Helmersson-Karlqvist; Anders Larsson; Johan Ärnlöv Journal: Ups J Med Sci Date: 2016-06-20 Impact factor: 2.384
Authors: Agnieszka Gala-Błądzińska; Paulina Dumnicka; Beata Kuśnierz-Cabala; Katarzyna Rybak; Ryszard Drożdż; Agnieszka Żyłka; Marek Kuźniewski Journal: Biomed Res Int Date: 2017-08-06 Impact factor: 3.411